Targeted Oncology Staff

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma.

During a live virtual event, Matthew A. Gubens, MD, MS, and participants discussed their reactions to the ADAURA trial of osimertinib for patients with EGFR-positive non–small cell lung cancer.

Pierre Gholam, MD, discussed with participants concerning the toxicity and management of lenvatinib for hepatocellular cancer and how it compares with sorafenib.

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the LOTIS-2 trial of loncastuximab tesirine in patients with relapsed/refractory diffuse large B-cell lymphoma.

During a live virtual event, Faith E. Davies, MD, discussed treatment options for a patient with multiple myeloma who relapsed after multiple lines of treatment including autologous stem cell transplant.

During a Targeted Oncology case-based roundtable event, Timothy Kuzel, MD, discussed risk assessment and later-line treatment options for a patient diagnosed with metastatic renal cell carcinoma who received lenvatinib and pembrolizumab.

During a live virtual event, Matthew B. Rettig, MD, discussed the guidelines and practical considerations for giving the 4 approved agents for metastatic castration-sensitive prostate cancer.

During a Targeted Oncology case-based roundtable event, Arlene Siefker-Radtke discussed the second-line treatment options for a patient with urothelial carcinoma and the EV-301 trial of enfortumab vedotin.

During a Targeted Oncology case-based roundtable event, Sumit Madan, MD, discussed the case of a 55-year-old patient with multiple myeloma who was refractory to multiple lines of therapy.

During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent's use in high-risk, early-stage breast cancer.

During a live virtual event, Nicholas J. Vogelzang, MD, discussed the results of the CLEAR trial of lenvatinib for patients with advanced renal cell carcinoma.

During a Targeted Oncology case-based roundtable discussion, Javier Pinilla-Ibarz, MD, PhD, discusses risk factors and prophylactic options for tumor lysis syndrome.

During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy.

During a Targeted Oncology case-based roundtable event, Erin Crane, MD, MPH, discussed several phase 3 trials of new combinations for maintenance therapy of advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Rachel B. Salit, MD, discussed the case of a patient with acute graft versus host disease, steroid dependence, and therapy for steroid-refractory disease.

During a live virtual event, Ruben Mesa, MD, discussed the use and sequencing of JAK inhibitors and stem cell transplant for patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Jad Chahoud, MD, MPH, discussed the case of a patient who progresses while on pembrolizumab plus axitinib, then again while on cabozantinib.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the frontline treatment options for a patient with hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, David P. Carbone, MD, PhD, discussed molecular testing and treatment for a patient with late-stage non–small cell lung cancer.

During a live virtual event, Adam C. ElNaggar discussed with participants whether patients who respond to PARP inhibitors for advanced ovarian cancer should continue to receive them indefinitely.

During a Targeted Oncology case-based roundtable event, Luciano J. Costa, MD, PhD, discussed various treatment regiments for a patient with newly diagnosed multiple myeloma.

During a live virtual event, Matthew A. Gubens, MD, MS, discussed adjuvant chemotherapy using carboplatin or cisplatin in patients with EGFR-positive non–small cell lung cancer.

During a live virtual event, Pierre Gholam, MD, discussed treatment options for a patient with hepatocellular carcinoma who had serious medical conditions including cirrhosis, Crohn's disease, and variceal bleeding.

During a live virtual event, Philippe Armand, MD, PhD, discussed the results of the outcomes of clinical trials of tafasitamab plus lenalidomide as well as loncastuximab tesirine in diffuse large B-cell lymphoma.

During a live virtual event, Evan Yu, MD, discussed the choice of novel hormonal agent for a patient with nonmetastatic castration-resistant prostate cancer.

During a live virtual event, Sara Tolaney, MD, MPH, discussed the common issue of neutropenia in patients with triple-negative breast cancer who received sacituzumab govitecan in the ASCENT trial and in her clinical practice.

During a live virtual event, Adam C. ElNaggar, MD, discussed with participants their experiences with PARP inhibitors in patients with ovarian cancer.

During a live virtual event, Moshe Ornstein, MD, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and participants' experiences with these agents.

During a live virtual event, Daniel C. Danila, MD, discussed how to treat a patient with de novo metastatic castration-sensitive prostate cancer and monitor for disease progression.

During a Targeted Oncology case-based roundtable event, John M. Pagel, MD, PhD, discusses the case of a patient with diffuse large B-cell lymphoma who is not eligible for transplant.